Dr Lalchandani Labs Ltd.

lalchandanipathlab.com

CIN No : L85320DL2017PLC321605

To,

Date: June 19, 2023

Listing Department

Bombay Stock Exchange Limited (BSE)

Phiroze Jeejeebhoy Towers,

Dalal Street Mumbai-400001

Ref: Dr Lalchandani Labs Limited (Scrip: 541299)

Subject: Outcome of Board Meeting dated 19.06.2023

Dear Sir/ Madam,

Concerning the above-cited subject, we would like to inform you that pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, we are enclosing herewith;

- 1. Statement showing the Audited Financial Statement Result for the half year ended March 31, 2023 along with Auditors Report on Audited Financial Results is also enclosed herewith, and,
- 2. In Compliance with Regulation 33(3) (d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May, 2016 we declare that report of Statutory Auditors is with an unmodified opinion with respect to the Audited Financial Results of the Company for the half-year and year ended March 31, 2023 is enclosed herewith.
- 3. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, it is hereby informed that CS Archana R Jha is being resigned due to some personal exigencies from the post of Company Secretary and Compliance Officer as KMP of DR LALCHANDANI LABS LIMITED with the effect from close of business hours of February 28, 2023. The company takes her resignation on records in this board meeting.

The said meeting of the Board of Directors commenced at 4.10 pm and concluded at 7.55 pm.

Request you to please take the same on your records.

Yours faithfully DAN/
For DR LALCHANDANI LABS LIMITE

Arjan Lalchandani Managing Director

DIN: 07014579

Encl: As Above









Dr Lalchandani Labs Ltd.

laichandanipathlab.com

CIN No : L85320DL2017PLC321605

To,

Date: June 19, 2023

Listing Department

Bombay Stock Exchange Limited (BSE)
Phiroze Jeejeebhoy Towers,
Dalal Street Mumbai-400001

Ref: Dr Lalchandani Labs Limited (Scrip: 541299)

Subject: Declaration of Audit Report with unmodified Opinion pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

Dear Sir/ Madam,

We hereby declare that Jain Agarwal & Company, Chartered Accountant (Firm's Registration No. 024866N), Statutory Auditors of the Company, have issued an Audit Report with an unmodified opinion on the Audited Financial Results of the Company for the year ended March 31, 2023.

The declaration is given pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations 2016, vide notification No. SEBI/ LAD-NRO/GN/2016-17/001 dated May 25, 2016 and circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.


This is for your information and records.


Yours faithfully,


For DR LALCHANDANI LABS LIMITED

Arjan Calchandani Managing Director DIN: 07014579











DR LALCHANDANI LABS LIMITED (CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048 Website: http://lalchandanipathlab.com, Email id: info@lalchandanipathlab.com Phone: 8010689689/ 8010998844

AUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS ON 31st MARCH 2023

Amount in Rs. Lacs

Sr. No.	Particulars	For the Year Ended			
		31.03.2023	31.03.2022		
1	Shareholders' Funds				
	(a) Share Capital	433.31	433.31		
	(b) Reserves and Surplus	458.94	615.22		
	(c) Money received against share warrants	- 1	-		
	Sub-total-Shareholders' Funds	892.24	1,048.53		
2	Share application money pending allotment				
3	Non Current Liabilities				
	(a) Long Term Borrowings	331.74	261.84		
	(b) Deferred Tax Liability	15.89	15.89		
	(c) Other Long Term Liabilities	-	-		
	(d) Long Term Provisions	-			
	Sub-total-Non Current Liabilities	347.62	277.73		
4	Current Liabilities				
	(a) Short Term Borrowings	308.74	252.57		
	(b) Trade Payables	-			
	(i) Total Outstanding dues of micro enterprises and small enterprises	46.85	41.07		
	(ii) Total Outstanding dues of creditors other than micro enterprises and small enterprises	72.14	102.08		
	(c) Other Current Liabilities	89.44	57.62		
	(d) Short Term Provisions	-	32.64		
	Sub-total-Current Liabilities	517.17	485.98		
	TOTAL EQUITY AND LIABILITIES	1,757.04	1,812.24		
II	ASSETS				
1	Non-Current Assets				
	(a) Fixed Assets				
	(i) Tangible assets	502.52	531.36		
	(ii) Intangible assets	36.67	43.76		
	(b) Non Current Investments	24.10	24.10		
	(c) Long Term Loans & Advances	106.74	121.64		
	(d) Other Non Current Assets	-	11.43		
	Sub-total-Non Current Assets	670.03	732.30		



2	Current Assets		
	(a) Current Investments	-	
	(b) Inventories	152.23	155.60
	(c) Trade Receivables	496.61	422.53
	l) Cash & cash equivalents	310.24	353.27
	(e) Short Term Loans & Advances	33.54	43.94
	(f) Other Current Assets	94.40	104.60
	Sub-total-Current Assets	1,087.02	1,079.94
	TOTAL ASSETS	1,757.04	1,812.24

For Dr Lalchandani Labs Limited

Dr. Arjan Lakhandani (Managing Director)

DIN: 07014579 Place: New Delhi Date: 19.06.2023

DR LALCHANDANI LABS LIMITED (CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048
Website: http://lalchandanipathlab.com, Email id: info@lalchandanipathlab.com
Phone: 8010689689/ 8010998844

AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND THE YEAR ENDED 31st MARCH 2023

Amount Rs. in Lakhs

Sr.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
No.		31.03.2023	30.09.2022	31.03.2022	31.03.2023	31.03.2022
		Audited	Un-audited	Audited	Audited	Audited
í	Revenue from Operations	275.63	228.39	325.77	504.02	1,127.87
II .	Other Income	-0.19	0.67	0.08	0.49	0.08
Ш	Total Revenue (I+II)	275.44	229.06	325.85	504.51	1,127.95
IV	Expenses					
	(a) Cost of materials consumed	63.76	74.67	56.22	138.43	323.88
	(b) Employee benefits expense	64.87	80.93	88.52	145.80	128.26
	(c) Finance Cost	51.12	48.30	33.21	99.42	56.83
	(d) Depreciation and amortisation expense	33.64	32.66	30.32	66.30	58.77
	(e) Other Expenses	121.08	89.77	135.45	210.84	435.50
	Total Expenses	334.47	326.32	343.73	660.79	1,003.24
V	Profit before exceptional and extraordinary items and tax (III - IV)	-59.02	-97.26	-17.88	-156.28	124.71
VI	Exceptional Items	3	- Ax	(5)	2575(- A
VII	Profit extraordinary items and tax (V - VI)	-59.02	-97.26	-17.88	-156.28	124.71
VIII	Extraordinary Items	+	23	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	227	2
IX	Profit before tax (VIII - IX)	-59.02	-97.26	-17.88	-156.28	124.71
Х	Tax Expenses:					
	(1) Current Tax	μ	-	-7.09	-	28.82
	(2) Deferred Tax		-	2.57		2.57



ΧI	Profit / (Loss) from Period from continuing oprtstions (VII -VIII)	-59.02	-97.26	-13.36	-156.28	93.33
XII	Profit (Loss) from discontinuing Operations		-	•		-
XIII	Tax Expense of Discontinuing operations		-	-	170	
XIV	Profit / (Loss) from Discontinuing oprtstions (After Tax XII- XIII)	ş - 0	-	-		-
XV	Profit (Loss) for the period (XI +XIV)	-59.02	-97.26	-13.36	-156.28	93.33
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)	•	-	-	-	-
	(a) Basic (Rs.)	-1.36	-2.24	-0.31	-3.61	2.15
	(b) Diluted (Rs.)	-1.36	-2.24	-0.31	-3.61	2.15

Notes:

- 1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 19th June, 2023.
- 2. The Company runs laboratories for carrying out pathological investigations.
- 3. There were no investor complaints received / pending as at 31st March, 2023.
- 4. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.
- 5. As per AS 20 Earnings Per Share (EPS) issued by ICAI weighted average number of equity shares are used as the denominator in calculating basic and diluted earnings per share giving effect to Right Issue, Bonus Issue and Initial Public Offer.
- 6. Previous year's figures have been regrouped/reclassified wherever required, to make them comparable with the figures for the current period.

For Dr Lalchandani Labs Limited

NEW DELHI

Dr. Arjan Valchandani (Managing Director) DIN: 07014579

Place: New Delhi Date: 19.06.2023

DR LALCHANDANI LABS LIMITED (CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048
Website: http://lalchandanipathlab.com, Email id: info@lalchandanipathlab.com
Phone: 8010689689/ 8010998844

Cash Flow Statement for the Year Ended 31st MARCH 2023

Amount Rs. in Lakhs

-	Particulars	F V 2022 22	EV 2024 22
	Faiticulais	F.Y.2022-23 Amount	F.Y.2021-22 Amount
	Cach Flaw From Operating Activities	Amount	Amount
	Cash Flow From Operating Activities Net Profit/(Loss) Before Tax	(156.30)	124.71
	사용 경험 경험 전문 경험 전환 경험 경험 경험 수 세계를 하고 있다면 하는 사용 수 있다.	(156.28)	124.71
	Adjustment For:	cc 20	F0 77
	Depreciation	66.30	58.77
	Interest Expense	99.42	11.48
	Asset Written Off	0.11	-
	Operating Profit Before Working Capital Changes	9.55	194.96
	Changes in Working Capital		
	Change in Sundry Debtors	(74.08)	(23.31)
	Change in Other Current Assets & Non Current Assets	21.64	(35.83)
	Change in Trade Payables	(24.16)	47.00
	Changes in Inventories	3.37	(87.91)
	Change in Other Current Liabilities	31.82	38.92
	Short Term Provisions	(32.64)	(28.82)
		(74.05)	(89.95)
	Net Cash Flows From Operating Activities(A)	(64.51)	105.01
	Cash Flow From Investing Activities		
	Purchase of Fixed Assets	(30.48)	(109.54)
3	Loans and Advances	25.30	(30.56)
	Net Cash Flow From Investing Activities (B)	(5.17)	(140.10)
	Cash Flow From Financing Activities		
	Long Term Borrowings taken	69.90	(2.24)
	Short Term Borrowings	56.17	112.84
	Interest Paid	(99.42)	(11.48)
	THE SECTOR	(33.42)	(11.40)
	Net Cash Flow From Financing Activities (C)	26.65	99.11
	Net Change in Cash (A+B+C)	(43.03)	64.02
	Cash and Cash Equivalents at the Beginning of Year	353.27	289.24
	Cash and Cash Equivalents at the End of Year	310.24	353.26

For Dr Latchandari trabs Limited

Dr. Arjan Lalchandani (Managing Director)

DIN: 07014579 Place: New Delhi Date: 19.06.2023



Jain Agarwal & Company

Chartered Accountants

Independent Auditor's report on Audited Half Yearly financial results and year to date results of the company pursuant to the regulation 33 of the SEBI (Listing obligations and disclosure requirements) Regulations, 2015.

TO

THE BOARD OF DIRECTORS OF DR LALCHANDANI LABS LIMITED

We have audited the accompanying half yearly and year to date financial results of Dr Lalchandani Labs Limited ("the company") which includes joint operations for the half year ended and year ended 31st March, 2023 ("the statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Our opinion is qualified for

- Company has not been able to pay installments for few months of term loans/unsecured loans during the previous financial year. Due to which they have not received the balance confirmation of various lenders. Company has valued the loan at the outstanding amount of Jan to Mar' 2023, i.e. till the time they have paid the installment of term loan/unsecured loan. So the interest/penal interest levied by the varous lenders during the last months have not been captured in the financial statements. Hence the loss suffered by the company is understated by the aforesaid interest/penal interest.
- Gratuity Liability & Leave Encashment Liability is not provided for in the books of accounts of the company and is thus not in accordance with Accounting Standard-15 on "Employee Benefits" issued by the Institute of Chartered Accountants of India.

Subject to above

In our opinion and to the best of our information and according to the explanations given to us these financial results: -

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the accounting standards and other accounting principles generally accepted in India of the net profit/ loss and other financial information for the half year and year ended 31st March, 2023.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act).

Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions

of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

- The company has generally been irregular in deposit of statutory dues viz ESI, PF and TDS for the financial year under consideration. (Details has been annexed in CARO Report);
- The company has also not deposited some of the dues of TDS Payable for the FY 2021-22 till date;
- During the Financial Year 2022-23, Company has defaulted in repayment of principal and interest thereon of various term loan and unsecured loans from banks & NBFC's despite of having significant cash & cash equivalents; and
- Company has not received balance confirmation from Amount receivables, loans & Advances and Amount Payables. We have relied on the management representations in regard to the confirmation of these balances.

Our opinion is not modified in respect of these matters. We have performed alternate audit procedures based on documents and information made available and relied upon by us.

Management's Responsibility for the Financial Statements

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance "with Regulations 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance "with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities: selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness* of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.



Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to
 fraud or error, design and perform audit procedures responsive to those risks, and obtain audit
 evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not
 detecting a material misstatement resulting from fraud is higher than for one resulting from
 error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the
 override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate to modify our opinion. Our Conclusion are based on the aduit evidence obtained up to the date of our auditor's report. However future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the
 disclosures, and whether the financial results represent the underlying transactions and events
 in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The statement includes the results for the half year ended March 31, 2023 being the balancing figure between the audited figures in respect of the full year ended March 31, 2023 and published unaudited half year of the current financial year, which were subject to limited review by us, as required under the listing regulations.

For and on behalf of Jain Agarwal and Company Firm' Registration No: 024866N

New Delhi

(Partner)

Membership No.: 521992

UDIN: 23521992BGYSGA7830

Place: New Delhi Date: June 19, 2023.